ArticleHuman vaccines & immunotherapeutics2024

Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States.

Elizabeth M La et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.